FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898490904> ?p ?o ?g. }

• W2898490904 endingPage "787" @default.
• W2898490904 startingPage "776" @default.
• W2898490904 abstract "Renal inflammation, leading to fibrosis and impaired function is a major contributor to the development of hypertension. The NLRP3 inflammasome mediates inflammation in several chronic diseases by processing the cytokines pro-interleukin (IL)-1β and pro-IL-18. In this study, we investigated whether MCC950, a recently-identified inhibitor of NLRP3 activity, reduces blood pressure (BP), renal inflammation, fibrosis and dysfunction in mice with established hypertension.C57BL6/J mice were made hypertensive by uninephrectomy and treatment with deoxycorticosterone acetate (2.4 mg/day, s.c.) and 0.9% NaCl in the drinking water (1K/DOCA/salt). Normotensive controls were uninephrectomized and received normal drinking water. Ten days later, mice were treated with MCC950 (10 mg/kg/day, s.c.) or vehicle (saline, s.c.) for up to 25 days. BP was monitored by tail-cuff or radiotelemetry; renal function by biochemical analysis of 24-h urine collections; and kidney inflammation/pathology was assessed by real-time PCR for inflammatory gene expression, flow cytometry for leucocyte influx, and Picrosirius red histology for collagen. Over the 10 days post-surgery, 1K/DOCA/salt-treated mice became hypertensive, developed impaired renal function, and displayed elevated renal levels of inflammatory markers, collagen and immune cells. MCC950 treatment from day 10 attenuated 1K/DOCA/salt-induced increases in renal expression of inflammasome subunits (NLRP3, ASC, pro-caspase-1) and inflammatory/injury markers (pro-IL-18, pro-IL-1β, IL-17A, TNF-α, osteopontin, ICAM-1, VCAM-1, CCL2, vimentin), each by 25-40%. MCC950 reduced interstitial collagen and accumulation of certain leucocyte subsets in kidneys of 1K/DOCA/salt-treated mice, including CD206+ (M2-like) macrophages and interferon-gamma-producing T cells. Finally, MCC950 partially reversed 1K/DOCA/salt-induced elevations in BP, urine output, osmolality, [Na+], and albuminuria (each by 20-25%). None of the above parameters were altered by MCC950 in normotensive mice.MCC950 was effective at reducing BP and limiting renal inflammation, fibrosis and dysfunction in mice with established hypertension. This study provides proof-of-concept that pharmacological inhibition of the NLRP3 inflammasome is a viable anti-hypertensive strategy." @default.
• W2898490904 created "2018-11-02" @default.
• W2898490904 creator A5009349672 @default.
• W2898490904 creator A5016982755 @default.
• W2898490904 creator A5025186205 @default.
• W2898490904 creator A5029379615 @default.
• W2898490904 creator A5032570989 @default.
• W2898490904 creator A5035866105 @default.
• W2898490904 creator A5036894368 @default.
• W2898490904 creator A5039076483 @default.
• W2898490904 creator A5044332524 @default.
• W2898490904 creator A5049936296 @default.
• W2898490904 creator A5051677621 @default.
• W2898490904 creator A5057421647 @default.
• W2898490904 creator A5059848603 @default.
• W2898490904 creator A5062825018 @default.
• W2898490904 creator A5067703598 @default.
• W2898490904 creator A5069893866 @default.
• W2898490904 creator A5072344236 @default.
• W2898490904 creator A5090230661 @default.
• W2898490904 date "2018-10-24" @default.
• W2898490904 modified "2023-10-18" @default.
• W2898490904 title "Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension" @default.
• W2898490904 cites W1482850806 @default.
• W2898490904 cites W1538633038 @default.
• W2898490904 cites W1588678169 @default.
• W2898490904 cites W1608457896 @default.
• W2898490904 cites W1782356084 @default.
• W2898490904 cites W1874970247 @default.
• W2898490904 cites W1953447169 @default.
• W2898490904 cites W1967763945 @default.
• W2898490904 cites W1969979138 @default.
• W2898490904 cites W1972483153 @default.
• W2898490904 cites W1974744480 @default.
• W2898490904 cites W1996348084 @default.
• W2898490904 cites W2009800174 @default.
• W2898490904 cites W2011811777 @default.
• W2898490904 cites W2020675784 @default.
• W2898490904 cites W2028823314 @default.
• W2898490904 cites W2054796764 @default.
• W2898490904 cites W2074149689 @default.
• W2898490904 cites W2076583198 @default.
• W2898490904 cites W2097283404 @default.
• W2898490904 cites W2100892070 @default.
• W2898490904 cites W2102671607 @default.
• W2898490904 cites W2108264583 @default.
• W2898490904 cites W2112309389 @default.
• W2898490904 cites W2113087028 @default.
• W2898490904 cites W2114570899 @default.
• W2898490904 cites W2115181506 @default.
• W2898490904 cites W2119098586 @default.
• W2898490904 cites W2129347383 @default.
• W2898490904 cites W2135372698 @default.
• W2898490904 cites W2140637559 @default.
• W2898490904 cites W2156816291 @default.
• W2898490904 cites W2157863043 @default.
• W2898490904 cites W2161038680 @default.
• W2898490904 cites W2335187016 @default.
• W2898490904 cites W2419316064 @default.
• W2898490904 cites W2462773201 @default.
• W2898490904 cites W2473716039 @default.
• W2898490904 cites W2547889494 @default.
• W2898490904 cites W2562544903 @default.
• W2898490904 cites W2588874415 @default.
• W2898490904 cites W2605197610 @default.
• W2898490904 cites W2623847043 @default.
• W2898490904 cites W2734949631 @default.
• W2898490904 cites W2748400555 @default.
• W2898490904 cites W4313310005 @default.
• W2898490904 doi "https://doi.org/10.1093/cvr/cvy252" @default.
• W2898490904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6432065" @default.
• W2898490904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30357309" @default.
• W2898490904 hasPublicationYear "2018" @default.
• W2898490904 type Work @default.
• W2898490904 sameAs 2898490904 @default.
• W2898490904 citedByCount "146" @default.
• W2898490904 countsByYear W28984909042018 @default.
• W2898490904 countsByYear W28984909042019 @default.
• W2898490904 countsByYear W28984909042020 @default.
• W2898490904 countsByYear W28984909042021 @default.
• W2898490904 countsByYear W28984909042022 @default.
• W2898490904 countsByYear W28984909042023 @default.
• W2898490904 crossrefType "journal-article" @default.
• W2898490904 hasAuthorship W2898490904A5009349672 @default.
• W2898490904 hasAuthorship W2898490904A5016982755 @default.
• W2898490904 hasAuthorship W2898490904A5025186205 @default.
• W2898490904 hasAuthorship W2898490904A5029379615 @default.
• W2898490904 hasAuthorship W2898490904A5032570989 @default.
• W2898490904 hasAuthorship W2898490904A5035866105 @default.
• W2898490904 hasAuthorship W2898490904A5036894368 @default.
• W2898490904 hasAuthorship W2898490904A5039076483 @default.
• W2898490904 hasAuthorship W2898490904A5044332524 @default.
• W2898490904 hasAuthorship W2898490904A5049936296 @default.
• W2898490904 hasAuthorship W2898490904A5051677621 @default.
• W2898490904 hasAuthorship W2898490904A5057421647 @default.
• W2898490904 hasAuthorship W2898490904A5059848603 @default.
• W2898490904 hasAuthorship W2898490904A5062825018 @default.
• W2898490904 hasAuthorship W2898490904A5067703598 @default.

• next